Qure.ai’s qER-CTA Solution Cleared for Analysis of CTA Scans of Suspected LVOs

October 22, 2025—Qure.ai announced FDA 510(k) clearance for its qER-CTA artificial intelligence (AI) solution, which is designed to analyze CTA scans for suspected large vessel occlusions (LVOs) in the brain.

According to the company, the neurocritical algorithm solution can review the internal carotid artery and the M1 segment of the middle cerebral artery in adults (age ≥ 22 years) to enable faster triage and specialist notification in emergency care scenarios. Qure.ai noted that this clearance expands its FDA-cleared portfolio in neurocritical findings and early cancer detection and builds on its suite of AI solutions for neurocritical conditions in acute care, including the triage of intracranial hemorrhages, and other critical brain emergencies.

“FDA clearances for AI algorithms like this represent an encouraging step toward deeper AI adoption in clinical practice,” commented Ajith Thomas, MD, in the company’s press release. “The qER-CTA algorithm’s ability to triage LVOs will complement existing AI tools for critical CT findings.”

Dr. Thomas, who is Chairman, Department of Neurosurgery at Cooper University Healthcare in Camden, New Jersey, continued, “This integration promises to fundamentally change traditional workflows, significantly reducing time to treatment in emergency scenarios and strengthening clinical decision-making.

 “If left unidentified, LVOs can rapidly cause ischemic strokes, leading to devastating disability and mortality without timely intervention. AI’s capacity to flag potential occlusions, support rapid triage, and notify specialists sooner has the meaningful potential to dramatically improve patient outcomes.”